Migraine & Migraine Management: A Review

  • Posted on: 31 March 2018
  • By: admin

Pharma Admission

igmpi

pharma admission

igmpi

 

 

Magazine HomeEditorial BoardLatest IssuesAuthor GuidelinesContact Us


April 2018 ARTICLE LIST >>

PharmaTutor (April - 2018)

 

ISSN: 2347 - 7881
(Volume 6, Issue 4)

 

Received On: 05/02/2018; Accepted On: 12/03/2018; Published On: 01/04/2018

 

AUTHORS:
Muthyala Nagavamsidhar*, Qadrie ZL, Suman A
Department of Pharmacy Practice,
Pratishta Institute of Pharmaceutical Sciences,
Suryapet, Hyderabad, Telangana
*nagavamsi.muthyala@gmail.com

 

 

ABSTRACT:
Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. The WHO has rated migraine amongst the top 20 most disabling life time conditions. Migraine is a pervasive and debilitating, chronic neurological painful disorder, affecting from 15% to 29% of the general population. It is the second most common cause of headache characterized by recurrent episodes of headache and associated symptoms i.e. nausea, sensitivity to light and noise that typically last from 4 to 72 hours which is divided into four phases. Migraine is well explained with three hypothesis i.e., vascular, platelet, central nervous system. It affects people of all groups, sexes, races and social classes around the globe. Migraine can occur due to various trigger factors and can be managed with both pharmacological and non-pharmacological treatment.

 

 

How to cite this article: Muthyala N, Qadrie ZL, Suman A; Migraine & Migraine Management: A Review; PharmaTutor; 2018; 6(4); 8-17; http://dx.doi.org/10.29161/PT.v6.i4.2018.8

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML 

Download in Article PDF